BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report

Genes Chromosomes and Cancer

Volumn 55, Issue 10, 2016, Pages 803-813

  Pilato, Brunella ^a   Pinto, Rosamaria ^a   De Summa, Simona ^a   Petriella, Daniela ^a   Lacalamita, Rosanna ^a   Danza, Katia ^a   Paradiso, Angelo ^a   Tommasi, Stefania ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COPY NUMBER VARIATION; COST EFFECTIVENESS ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC COUNSELING; GENETIC VARIATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TURNAROUND TIME;

EID: 84981203332     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22383     Document Type: Article

References (35)

1. Artuso R, Fallerini C, Dosa L, Scionti F, Clementi M, Garosi G, Massella L, Epistolato MC, Mancini R, Mari F, Longo I, Ariani F, Renieri A, Bruttini M. 2012. Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet 20:50–57.
2. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. 2007. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: A systematic review. Int J Cancer 121:225–231.
3. Bragg LM, Stone G, Butler MK, Hugenholtz P, Tyson GW. 2013. Shining a light on dark sequencing: Characterising errors in Ion Torrent PGM data. PLoS Comput Biol 9:e1003031.
4. Chan M, Ji SM, Yeo ZX, Gan L, Yap E, Yap YS, Ng R, Tan PH, Ho GH, Ang P, Lee AS. 2012. Development of a next-generation sequencing method for BRCA mutation screening: A comparison between a high-throughput and a benchtop platform. J Mol Diagn 14:602–612.
5. Costa JL, Sousa S, Justino A, Kay T, Fernandes S, Cirnes L, Schmitt F, Machado JC. 2013. Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting. Hum Mutat 34:629–635.
6. Dacheva D, Dodova R, Popov I, Goranova T, Mitkova A, Mitev V, Kaneva R. 2015. Validation of an NGS approach for diagnostic BRCA1/BRCA2 mutation testing. Mol Diagn Ther 19:119–130.
7. D'Argenio V, Esposito MV, Telese A, Precone V, Starnone F, Nunziato M, Cantiello P, Iorio M, Evangelista E, D'Aiuto M, Calabrese A, Frisso G, D'Aiuto G, Salvatore F. 2015. The molecular analysis of BRCA1 and BRCA2: Next-generation sequencing supersedes conventional approaches. Clin Chim Acta 446:221–225.
8. Ewald IP, Ribeiro PL, Palmero EI, Cossio SL, Giugliani R, Ashton-Prolla P. 2009. Genomic rearrangements in BRCA1 and BRCA2: A literature review. Genet Mol Biol 32:437–446.
9. Feliubadalo L, Lopez-Doriga A, Castellsague E, del Valle J, Menendez M, Tornero E, Montes E, Cuesta R, Gomez C, Campos O, Pineda M, Gonzalez S, Moreno V, Brunet J, Blanco I, Serra E, Capella G, Lazaro C. 2013. Next-generation sequencing meets genetic diagnostics: Development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet 21:864–870.
10. Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M, Corless CL. 2015. Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn 17:53–63.
11. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, Sanford T, Buddavarapu K, Krosting J, Garmire L, Wylie D, Shinde R, Beaudenon S, Alexander EK, Mambo E, Adai AT, Latham GJ. 2013. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15:234–247.
12. Li X, Buckton AJ, Wilkinson SL, John S, Walsh R, Novotny T, Valaskova I, Gupta M, Game L, Barton PJ, Cook SA, Ware JS. 2013. Towards clinical molecular diagnosis of inherited cardiac conditions: A comparison of bench-top genome DNA sequencers. PLoS One 8:e67744.
13. Marsh DJ, Howell VM. 2010. The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes. Methods Mol Biol 653:133–145.
14. Minucci A, Scambia G, Santonocito C, Concolino P, Canu G, Mignone F, Saggese I, Guarino D, Costella A, Molinario R, De Bonis M, Ferrandina G, Petrillo M, Scaglione GL, Capoluongo E. 2015. Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: The experience at Gemelli hospital and a literature review. Expert Rev Mol Diagn 15:1383–1403.
15. O'Sullivan Coyne G, Chen A, Kummar S. 2015. Delivering on the promise: Poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 27:475–481.
16. Ozcelik H, Shi X, Chang MC, Tram E, Vlasschaert M, Di Nicola N, Kiselova A, Yee D, Goldman A, Dowar M, Sukhu B, Kandel R, Siminovitch K. 2012. Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. J Mol Diagn 14:467–475.
17. Pilato B, De Summa S, Danza K, Lambo R, Paradiso A, Tommasi S. 2010. Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: A first case report. Breast Cancer Res Treat 124:875–878.
18. Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D'Amico C, Paradiso A, Tommasi S. 2011. Mutations and polymorphic BRCA variants transmission in breast cancer familial members. Breast Cancer Res Treat 125:651–657.
19. Pilato B, De Summa S, Danza K, Lacalamita R, Lambo R, Sambiasi D, Paradiso A, Tommasi S. 2014. Genetic risk transmission in a family affected by familial breast cancer. J Hum Genet 59:51–53.
20. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV; IARC Unclassified Genetic Variants Working Group. 2008. Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282–1291.
21. Pujade-Lauraine E, Combe P. 2015. Olaparib in ovarian cancer with BRCA mutation. Bull Cancer 102:S82–S84.
22. Radice P, De Summa S, Caleca L, Tommasi S. 2011. Unclassified variants in BRCA genes: Guidelines for interpretation. Ann Oncol 1:i18–i23.
23. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, Leamon JH, Johnson K, Milgrew MJ, Edwards M, Hoon J, Simons JF, Marran D, Myers JW, Davidson JF, Branting A, Nobile JR, Puc BP, Light D, Clark TA, Huber M, Branciforte JT, Stoner IB, Cawley SE, Lyons M, Fu Y, Homer N, Sedova M, Miao X, Reed B, Sabina J, Feierstein E, Schorn M, Alanjary M, Dimalanta E, Dressman D, Kasinskas R, Sokolsky T, Fidanza JA, Namsaraev E, McKernan KJ, Williams A, Roth GT, Bustillo J. 2011. An integrated semiconductor device enabling non-optical genome sequencing. Nature 475:348–352.
24. Shanks ME, Downes SM, Copley RR, Lise S, Broxholme J, Hudspith KA, Kwasniewska A, Davies WI, Hankins MW, Packham ER, Clouston P, Seller A, Wilkie AO, Taylor JC, Ragoussis J, Nemeth AH. 2013. Next-generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals a much higher detection rate in early-onset disease. Eur J Hum Genet 21:274–280.
25. Sluiter MD, van Rensburg EJ. 2011. Large genomic rearrangements of the BRCA1 and BRCA2 genes: Review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 125:325–349.
26. Tan DS, Kaye SB. 2015. Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: Same or different? Am Soc Clin Oncol Educ Book 114–121.
27. Tarabeux J, Zeitouni B, Moncoutier V, Tenreiro H, Abidallah K, Lair S, Legoix-Ne P, Leroy Q, Rouleau E, Golmard L, Barillot E, Stern MH, Rio-Frio T, Stoppa-Lyonnet D, Houdayer C. 2014. Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model. Eur J Hum Genet 22:535–541.
28. Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A. 2008. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 644:64–70.
29. Trujillano D, Weiss ME, Koster J, Papachristos EB, Werber M, Kandaswamy KK, Marais A, Eichler S, Creed J, Baysal E, Jaber IY, Mehaney DA, Farra C, Rolfs A. 2015a. Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR. Mol Genet Genomic Med 3:396–403.
30. Trujillano D, Weiss ME, Schneider J, Koster J, Papachristos EB, Saviouk V, Zakharkina T, Nahavandi N, Kovacevic L, Rolfs A. 2015b. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. J Mol Diagn 17:162–170.
31. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, Wells WA, Amos CI. 2014. Routine use of the Ion Torrent AmpliSeq Cancer HotSpot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 52:707–714.
32. Vogel U, Szczepanowski R, Claus H, Junemann S, Prior K, Harmsen D. 2012. Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information. J Clin Microbiol 50:1889–1894.
33. Yeo ZX, Chan M, Yap YS, Ang P, Rozen S, Lee AS. 2012. Improving Indel Detection Specificity of the Ion Torrent PGM Benchtop Sequencer. PLoS One 7:e45798.
34. Yeo ZX, Wong JC, Rozen SG, Lee AS. 2014. Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes. BMC Genomics 15:516.
35. Yousem SA, Dacic S, Nikiforov YE, Nikiforova M. 2013. Pulmonary Langerhans cell histiocytosis: Profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 143:1679–1684.